Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 78
1980 187
1981 247
1982 311
1983 349
1984 402
1985 429
1986 482
1987 491
1988 477
1989 568
1990 596
1991 534
1992 526
1993 507
1994 513
1995 452
1996 462
1997 493
1998 488
1999 461
2000 469
2001 451
2002 429
2003 541
2004 510
2005 611
2006 660
2007 503
2008 508
2009 433
2010 488
2011 745
2012 600
2013 624
2014 616
2015 589
2016 599
2017 802
2018 984
2019 1265
2020 1759
2021 1710
2022 1304
2023 1232
2024 1262
2025 663

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,234 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. J Am Acad Dermatol. 2023. PMID: 35820547 Free article. Clinical Trial.
Bromhidrosis treatment modalities: A literature review.
Malik AS, Porter CL, Feldman SR. Malik AS, et al. J Am Acad Dermatol. 2023 Jul;89(1):81-89. doi: 10.1016/j.jaad.2021.01.030. Epub 2021 Jan 20. J Am Acad Dermatol. 2023. PMID: 33482257 Review.
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, Hamzavi I, Jaleel T, Kimball AB, Kirby JS, Kirchhof MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, Naik HB. Garg A, et al. J Am Acad Dermatol. 2022 May;86(5):1092-1101. doi: 10.1016/j.jaad.2021.01.059. Epub 2021 Jan 23. J Am Acad Dermatol. 2022. PMID: 33493574 Free PMC article. Review.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Refining dermatomyositis.
Heymann WR. Heymann WR. J Am Acad Dermatol. 2024 Dec;91(6):1076-1077. doi: 10.1016/j.jaad.2024.10.003. Epub 2024 Oct 10. J Am Acad Dermatol. 2024. PMID: 39393549 No abstract available.
Reply.
Dubin DP, Lin MJ, Leight HM, Farberg AS, Torbeck RL, Burton WB, Khorasani H. Dubin DP, et al. J Am Acad Dermatol. 2021 Jun;84(6):e287. doi: 10.1016/j.jaad.2021.02.002. Epub 2021 Feb 4. J Am Acad Dermatol. 2021. PMID: 33549651 No abstract available.
Reply.
Chen Q, Tang Y, Li J. Chen Q, et al. J Am Acad Dermatol. 2021 Sep;85(3):e169. doi: 10.1016/j.jaad.2021.01.091. Epub 2021 Jan 30. J Am Acad Dermatol. 2021. PMID: 33529699 No abstract available.
25,234 results
You have reached the last available page of results. Please see the User Guide for more information.